This study was carried out on 14 asthmatic childen aged 7–13 years. They all received three preparations (aminophylline by intravenous infusion, lysine theophyllinate orally in solution and slow release theophylline orally as capsules) in a single dose of 100 mg active ingredient in a crossover design. Plasma theophylline concentrations, determined by a fluorescent polarization immunoassay, were evaluated both by compartmental and non-compartmental analysis. After administration of slow release theophylline, its maximum plasma concentration and the time needed to reach this were (± SD) 3.19 ± 0.63 μg/ml and 8.71 ± 2.30 h, respectively, compared to 4.51 ± 0.94 μg/ml and 1.96 ± 0.85 h, respectively, for the oral normal release solution. Mean absolute and relative percentage bioavailabilities for slow release theophylline in asthmatic children were (± SD) 92.7 ± 23.2% and 83.14 ± 14.69%, respectively. These are similar to the values found with other slow release formulations in paediatric patients.

01 Apr 1986·British Journal of Clinical PharmacologyQ2 · MEDICINE

The interaction between i.v. theophylline and chronic oral dosing with slow release nifedipine in volunteers.

Q2 · MEDICINE

Article

Author: Johnston, A. ; Shah, K. ; Jackson, S. H. D. ; Debbas, N. M. G. ; Turner, P. ; Peverel-Cooper, C. A.

Eight healthy volunteers received a 5 min i.v. infusion of lysine theophylline, equivalent to 197 mg anhydrous theophylline, both before (day 1) and during (day 5) steady state chronic oral dosing with slow release nifedipine 20 mg 12 hourly. A theophylline pharmacokinetic profile was performed on day 1 and day 5 and a nifedipine pharmacokinetic profile was performed on day 4 and day 5. The greatest difference in serum theophylline concentrations was seen at the first sampling time (5 min after completion of the infusion) with a mean concentration of 9.9 mg l‐1 during nifedipine administration and 14.6 mg l‐1 with theophylline alone. Thereafter, the difference fell to approximately 1 mg l‐1 until 6 h when they became almost identical. Repeated measures analysis of variance using the theophylline serum concentrations at each of ten time points over 8 h as the repeated measures showed a small but significant effect of nifedipine (F(1,151) = 7.0, P less than 0.01) on serum theophylline concentrations. Mean volume of distribution (V) rose from 0.33 +/‐ 0.07 to 0.39 +/‐ 0.06 1 kg‐1 corrected body weight (CBW) in the presence of nifedipine (t = 2.23, P = 0.052). Theophylline clearance, area under the curve to 8 h AUC (0‐8), area under the curve to infinity AUC (0‐infinity) and elimination half‐life (t1/2) did not change appreciably. No statistically significant changes in nifedipine pharmacokinetics occurred in the presence of theophylline.

01 Aug 1984·British Journal of Clinical PharmacologyQ2 · MEDICINE

The stimulatory effects of caffeine, theophylline, lysine‐theophylline and 3‐isobutyl‐1‐methylxanthine on human sperm motility.

Q2 · MEDICINE

Article

Author: Turner, P. ; Kilfeather, S. A. ; Pearson, R. M. ; Jiang, C. S.

The potencies of caffeine, theophylline, lysine‐theophylline and 3‐ isobutyl‐1‐methylxanthine (IBMX) in stimulating sperm motility have been compared, and we have found IBMX to be significantly more potent than the other three compounds, which did not exhibit significant differences in potency from each other.

100 Deals associated with Lysine Theophyllinate

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Asthma	China	Wuhan Fuxing Biotechnology Pharmaceutical Co., Ltd.	01 Jan 1997
Bronchitis, Chronic	China	Wuhan Fuxing Biotechnology Pharmaceutical Co., Ltd.	01 Jan 1997

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Lysine Theophyllinate

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation